Positron emission tomography (PET) is a type of nuclear medicine procedure that measures metabolic activity of the cells of body tissues. PET is actually a combination of nuclear medicine and biochemical analysis. A positron emission tomography (PET) scan is an imaging test that helps reveal how your tissues and organs are functioning. A PET scan uses a radioactive drug (tracer) to show this activity. A PET Scan (or Positron Emission Tomography) is a non-invasive, diagnostic examination that finds information about the activity of different parts of the body.
- Increasing Demand for PET Analysis in Radio Pharmaceuticals
- Integration of X-ray Tomography (CT) into PET
- Oncology is Expected to Hold the Largest Share of the Positron Emission Tomography Market
- Shorter Half-life of Radioisotopes
- Stringent Regulatory Guidelines
Technological Advancements in Pet Imaging for Oncology and Advanced Diagnostics Applications
Players Covered in the Study are:
Gamma Medica Inc. (United States), GE Healthcare (United States), Neusoft Medical Systems (China), Oncovision (Spain), Koninklijke Philips NV (Netherlands), Positron Corporation (United States), Siemens AG (Germany), Toshiba (Japan), Hitachi (Japan) and United Imaging (China)
The Global Positron Emission tomography market is gaining huge competition due to involvement of United States companies that constantly invest in research & development to meet market expectation with new innovation.